Bristol-Myers Squibb's (BMS) Opdivo, the first in a new generation on immunotherapy cancer drugs approved to treat non-small cell lung cancer (NSCLC) has been rejected by NICE in draft guidance.

Different parts of Medicare can provide coverage for cancer ... Opdivo infusions that a person gets as an outpatient in a health center or doctor’s clinic. Medicare Part D covers prescription ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer. Opdivo (nivolumab) plus Yervoy (ipilimumab) improved ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Opdivo (nivolumab) is an immunotherapy treatment for advanced lung cancer or other cancers that have been resistant to other treatments. Though this is a newer drug, Medicare covers the cost of ...